|
시장보고서
상품코드
2084833
데스모이드 종양 시장 : 약제 종류별, 유통 채널별, 지역별Desmoid Tumors Market, By Drug Type, By Distribution channel, By Geography |
||||||
데스모이드 종양 시장은 2026년에 33억 610만 달러 규모가 될 것으로 추정되며, 2033년까지 54억 1,390만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.3%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 33억 610만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 7.30% | 예측 금액(2033년) | 54억 1,390만 달러 |
데스모이드 종양은 뼈, 인대, 근육 등의 구조에 강도와 유연성을 부여하는 조직인 결합 조직에서 발생하는 비정상적인 증식입니다. 데스모이드 종양은 섬유질이며, 흉터 조직과 매우 유사합니다. 다른 부위로 전이되지 않기 때문에 일반적으로 암(악성)으로 간주되지 않습니다. 그러나 주변 조직으로 침습적으로 침윤하는 경우가 있어, 외과적으로 절제하기가 매우 어려운 경우가 있습니다. 이러한 종양은 겉보기에는 완전히 절제된 후에도 재발하는 경우가 종종 있습니다. 데스모이드 종양의 가장 흔한 증상은 통증입니다. 그 밖의 징후나 증상은 종양이 주변 조직으로 침윤함으로써 발생하는 경우가 많으며, 종양의 크기와 위치에 따라 다릅니다.
시장 역학
이 시장에서 활동하는 주요 기업들은 데스모이드 종양 치료제 개발에 주력하고 있으며, 이것이 예측 기간 동안 시장 성장을 견인할 것으로 전망됩니다. 예를 들어, 2022년 7월, 희귀 종양 및 침습성이 높은 암 환자를 위한 저분자 의약품의 발굴 및 상용화에 주력하는 임상 단계의 종양학 기업인 Ayala Pharmaceuticals, Inc.는 데스모이드 종양에 대한 AL102를 평가하는 진행 중인 RINGSIDE 2/3상 임상시험(Pivotal)의 파트 A에 대해 긍정적인 중간 결과를 발표했습니다. AL102는 강력하고 특이적인 GSI(감마 세크레타제 억제제)인 경구용 약물입니다. 또한, 데스모이드 종양 연구에 자금을 지원하는 ‘데스모이드 종양 재단’의 존재가 예측 기간 동안 해당 국가의 시장 성장을 견인할 것으로 예상됩니다. 예를 들어, 캐나다 데스모이드 종양 재단(DFC)은 데스모이드 종양 치료법 연구에 자금을 지원하는 데 전념하는 캐나다의 등록 자선 단체입니다. DFC는 데스모이드 종양 연구에 자금을 지원하고, 이 희귀 질환의 치료법 개발에 전력을 다하고 있습니다. DFC는 치료법 개발을 가속화하기 위해 서로 다른 기관의 연구자들 간의 협력을 지원하고 있습니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 전 세계 데스모이드 종양 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 소개하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 데스모이드 종양 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 데스모이드 종양 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 데스모이드 종양 시장 : 약제 종류별(2021-2033년)
제5장 세계의 데스모이드 종양 시장 : 유통 채널별(2021-2033년)
제6장 세계의 데스모이드 종양 시장 : 지역별(2021-2033년)
제7장 경쟁 구도
제8장 섹션
KSM 26.07.20Desmoid Tumors Market is estimated to be valued at USD 3,306.1 Mn in 2026 and is expected to reach USD 5,413.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3,306.1 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.30% | 2033 Value Projection: | USD 5,413.9 Mn |
A desmoid tumor is an abnormal growth that arises from connective tissue, which is the tissue that provides strength and flexibility to structures such as bones, ligaments, and muscles. Desmoid tumors are fibrous, much like scar tissue. They are generally not considered cancerous (malignant) because they do not spread to other parts of the body. However, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. These tumors often recur, even after apparently complete removal. The most common symptom of desmoid tumors is pain. Other signs and symptoms, which are often caused by growth of the tumor into surrounding tissue, vary based on the size and location of the tumor.
Market Dynamics
Key players operating in the market are focused on developing drugs for the treatment of desmoid tumors which is expected to drive the market growth over the forecast period. For instance, in July 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focusing on discovering and commercializing small molecule medicines for patients with uncommon tumors and aggressive cancers, announced positive interim findings from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical study assessing AL102 in desmoid tumors. AL102 is an oral gamma-secretase inhibitor that is powerful and specific GSI. Moreover, the presence of desmoid tumor foundation providing funds for desmoid tumor research, is expected to drive the market growth in the country over the forecast period. For instance, Desmoid Tumour Foundation of Canada (DFC) is a registered Canadian charity dedicated to funding research for cure for desmoid tumors. DFC is dedicated to funding desmoid tumor research and finding a cure for this rare disease. DFC supports the collaboration between researchers from different institutions to expedite the development of cure.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global desmoid tumor market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies.
- Key companies covered as a part of this study Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin, Zydus Lifesciences, Mylan N.V., Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex Inc., Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global desmoid tumor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Desmoid Tumors Market.
Market Segmentation
- By Drug Type (Revenue, USD Mn, 2021 - 2033)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
- By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players
- Horizon Therapeutics Plc
- Strides Pharma Science Limited
- Teva Pharmaceutical Industries Ltd.
- Amneal Pharmaceuticals LLC
- Hikma Pharmaceuticals PLC
- Natco Pharma Ltd
- Lupin
- Zydus Lifesciences
- Mylan N.V.
- Assertio Holdings, Inc.
- Mayne Pharma Group Limited
- Alembic Pharmaceuticals Limited
- Aprazer
- Ayala Pharmaceuticals
- SpringWorks Therapeutics, Inc.
- Iterion Therapeutics
- Novartis AG
- Apotex Inc.
- Bayer AG.
- Sun Pharmaceutical Industries Ltd
- Reddy's Laboratories Ltd.
- Endo International plc
- Abbott
- Getwell Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Reimbursement Scenario
- Pipeline Analysis
- Collaboration Scenario
- Treatment Option Analysis
- Treatment Safety and Efficacy Analysis
- Site of Activity (Mode of Action)
- Treatment Algorithm for Desmoid Tumours
- Disease Awareness Programs
- Risk and Adverse effects
- Healthcare spending by Country
- Unmet Needs
- Treatment Rate
4. Global Desmoid Tumors Market, By Drug Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Hormone Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Desmoid Tumors Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Desmoid Tumors Market, By Region, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Horizon Therapeutics Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strides Pharma Science Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amneal Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Natco Pharma Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lupin
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Assertio Holdings, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mayne Pharma Group Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Alembic Pharmaceuticals Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aprazer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Ayala Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SpringWorks Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Iterion Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Apotex Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abbott
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Getwell Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Horizon Therapeutics Plc
8. Section
- Research Methodology
- About us
